Home » Posts tagged with » Oncology
Deciphera gets Qinlock FDA approval for fourth-line advanced GIST

Deciphera gets Qinlock FDA approval for fourth-line advanced GIST

Qinlock FDA approval : Deciphera Pharmaceuticals has been granted approval from the US Food and Drug Administration (FDA) for Qinlock (ripretinib) in advanced gastrointestinal stromal tumor (GIST) in adult patients who had prior treatment with three or more kinase inhibitors, including imatinib. The decision from the FDA marks Qinlock as the first drug approved in […]

Selpercatinib FDA approval : Lilly’s therapy approved for treatment of lung and thyroid cancers with RET alteration

Selpercatinib FDA approval : The US Food and Drug Administration (FDA) has approved Eli Lilly and Company’s Retevmo (selpercatinib) capsules for the treatment of three types of tumors – non-small cell lung cancer, medullary thyroid cancer and other types of thyroid cancers. The approvals are for the drug to be used in patients whose tumors […]

Continue reading …
Lilly bags Retevmo FDA approval for RET-driven lung and thyroid cancers

Retevmo FDA approval : Eli Lilly and Company (Lilly) has secured approval from the US Food and Drug Administration (FDA) for Retevmo (selpercatinib, 40mg and 80mg capsules) for the treatment of adults with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC). Retevmo has also been approved by the FDA for the treatment […]

Continue reading …
Cyclica, Genome Institute of Singapore sign drug discovery partnership

Canadian biotech company Cyclica has signed a multi-year and multi-project drug discovery partnership with the Genome Institute of Singapore (GIS) in oncology and related diseases. The partners will undertake research efforts, which will span from polypharmacology profiling to novel compound design for diverse drug discovery programs. The collaboration will utilize the deep expertise of Genome […]

Continue reading …
FDA approves Opdivo + Yervoy for HCC previously treated with sorafenib

Bristol Myers Squibb has secured approval for the combination of Opdivo (nivolumab) 1 mg/kg and Yervoy (ipilimumab) 3 mg/kg from the US Food and Drug Administration (FDA) for the treatment of hepatocellular carcinoma (HCC) in patients who were previously treated with sorafenib. Approval for the indication has been issued under accelerated approval on the basis […]

Continue reading …
Gilead Sciences to acquire immuno-oncology company Forty Seven for $4.9bn

Gilead Sciences acquisition of Forty Seven : US biotech company Gilead Sciences has signed an all-cash deal worth around $4.9 billion to acquire Forty Seven, a clinical-stage immuno-oncology company based in California, as per the latest pharma acquisition news. The immuno-oncology company is being acquired by Gilead Sciences for $95.50 per share in cash. Through […]

Continue reading …
PADCEV, KEYTRUDA combination for advanced bladder cancer gets FDA breakthrough therapy status

PADCEV, KEYTRUDA combination : Astellas Pharma and Seattle Genetics said that the combination of PADCEV (enfortumab vedotin-ejfv) and Merck’s anti-PD-1 therapy KEYTRUDA (pembrolizumab) has been given breakthrough therapy designation from the US Food and Drug Administration (FDA) in first-line advanced bladder cancer. The FDA breakthrough therapy status for PADCEV, KEYTRUDA combination is for the treatment […]

Continue reading …
ALX Oncology raises $105m to advance clinical development of ALX148

ALX Oncology, a clinical-stage immuno-oncology company based in California, has raised $105 million in a Series C equity financing round led by Vivo Capital. The US biotech company is focused on developing therapies to block the CD47 checkpoint mechanism. ALX Oncology will use the Series C proceeds to help expand the clinical development of its […]

Continue reading …
Pinpoint Therapeutics secures funds for developing autophagy inhibitors for cancer

Pinpoint Therapeutics, a US biopharma company focused on developing autophagy inhibitors for cancer treatment, has secured $1 million in debt financing led by California-based venture capital firm Kairos Ventures. The preclinical stage company was founded in 2018 through PCI Ventures, a division of the Penn Center for Innovation (PCI) at the University of Pennsylvania. It […]

Continue reading …
Merck acquires ArQule for $2.7bn to further diversify oncology pipeline

Merck acquisition of ArQule : Merck has completed its previously announced acquisition of ArQule for $20 per share or about $2.7 billion as per the latest pharma acquisition news. The pharma giant announced the deal in December 2019 in a move to further diversify its oncology pipeline with the Massachusetts-based ArQule focused on developing kinase […]

Continue reading …
Page 1 of 9123Next ›Last »